welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
unknown status
Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping
study id #: NCT01772043
condition: Duchenne Muscular Dystrophy
status: unknown
purpose:We will utilize the Cooperative International Neuromuscular Research Group (CINRG) network to collect and store tissue and blood from patients with Duchenne muscular dystrophy (DMD) with specific genetic mutations within the dystrophin gene that could be treated by antisense oligonucleotide (AO) drugs.
mechanism of action: No pharmaceutical intervention
results: https://clinicaltrials.gov/ct2/show/results/NCT01772043
last updated: November 22, 2018
study details
study contacts
rareRelated
-
Electrical Impedance Myography and Ultrasound as Biomarkers of Duchenne Muscular DystrophyResearchers at Children's Hospital Bosto...
-
Study of Ataluren for Previously Treated Patients With nmDBMD in Europe, Israel, Australia, and CanadaDuchenne/Becker muscular dystrophy (DBMD...
-
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory AdolescentsThis single center open-label pilot stud...
-
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
-
Catabasis Quarterly: Updates on edasalonexent and clinical trialsWe are pleased to announce that we have ...
-
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
-
Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular...Pfizer Inc. has initiated a Phase 1b cli...
-
Cardiac and Skeletal Muscle Effects in the Randomized HOPE-Duchenne TrialObjective: To assess the feasibility, s...
-
Antisense Therapeutics to commence muscular dystrophy trialsAntisense Therapeutics is planning to un...
